Komori
Business alliance6029Artra Group CorporationInformation and Communications, Services and Others

Capital and business alliance with REMED JAPAN株式会社 and acquisition of its shares through subscription for a third-party allotment (making it an equity-method affiliate)

The Company will subscribe for REMED JAPAN’s third-party allotment of shares, pay in ¥78,077,000 and acquire 35% of the voting rights. As a result, REMED JAPAN will become an equity-method affiliate, and the Company is also expected to acquire the right to increase its voting interest to 51% through additional acquisition in the future.

Worth reading
76Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
78077000
¥
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Capital and Business Alliance
6029Artra Group Corporation
Alliance partnerREMED JAPAN 株式会社 / Remed Co., Ltd.
Details of the alliance
  1. 1

    Subscription for a third-party allotment (first stage: making REMED JAPAN an equity-method affiliate)

  2. 2

    Management Structure

  3. 3

    Right to acquire additional shares (second stage: making REMED JAPAN a consolidated subsidiary)

  4. 4

    Use of funds

  5. 5

    Exclusive distribution agreement and future developments

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

Numerical targets under the alliance

The Company will acquire 35% of REMED JAPAN’s voting rights and, in the second stage, is expected to exercise a call option during a specified period after finalization of the results for the fiscal year ending December 2028, increasing its voting interest to 51%.

Capital and personnel relationships

This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).

35.00%Our ownership stake in the partner’s shares
Number of shares acquired156,154 shares (35.0% voting rights ownership)
Acquisition price¥78,077,000
Dispatch of directors and officersThe Company and REMED JAPAN are each expected to nominate 2 directors, and the Company is expected to appoint an audit & supervisory board member. One director from each company is expected to be appointed as representative director.
Shareholding PolicyWhile the Company holds shares in REMED JAPAN, the exclusive distribution agreement may not be terminated, nor may prices be changed, without the Company’s consent. No additional acquisition exceeding 51% is currently planned.
About the partner
Business DescriptionSales, import and export, repair and maintenance, rental and leasing, and other activities involving medical equipment and medical supplies / Research, development, manufacture and sale of non-invasive electromagnetic medical devices, including transcranial magnetic stimulators (TMS), neuromuscular magnetic stimulators (NMS) and extracorporeal shock wave therapy devices (ESWT), for applications including neurorehabilitation, chronic pain and aesthetics
LocationChuo-ku, Tokyo / Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, South Korea
Share capital¥72.5 million / KRW 3.06 billion (approximately ¥306 million)
Net SalesFiscal year ended December 2025: ¥132.895 million / Fiscal year ended December 2025: KRW 24.505 billion (approximately ¥2.451 billion)
Operating profitFiscal year ended December 2025: operating loss of ¥39.639 million / Fiscal year ended December 2025: operating profit of KRW 726 million (approximately ¥73 million)
Impact on Business Performance

REMED JAPAN is expected to become an equity-method affiliate. The impact on the Company’s consolidated results has not been determined at this time, but is expected to be immaterial.

Date of board resolution17 November 2026Contract DateEarly December 2026 (予定)Share Acquisition Date and Payment DateEarly December 2026 (予定)
Agreements reached under this partnership
ItemDetails
Name of alliance partnerREMED JAPAN 株式会社, Remed Co., Ltd.
Alliance partner's business activitiesSales, import and export, repair and maintenance, rental and leasing, and other activities involving medical equipment and medical supplies / Research, development, manufacture and sale of non-invasive electromagnetic medical devices, including transcranial magnetic stimulators (TMS), neuromuscular magnetic stimulators (NMS) and extracorporeal shock wave therapy devices (ESWT), for applications including neurorehabilitation, chronic pain and aesthetics
Alliance partner's locationChuo-ku, Tokyo / Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, South Korea
Alliance partner's capital¥72.5 million / KRW 3.06 billion (approximately ¥306 million)
Alliance partner's net salesFiscal year ended December 2025: ¥132.895 million / Fiscal year ended December 2025: KRW 24.505 billion (approximately ¥2.451 billion)
Alliance partner's operating incomeFiscal year ended December 2025: operating loss of ¥39.639 million / Fiscal year ended December 2025: operating profit of KRW 726 million (approximately ¥73 million)
Type of allianceCapital and Business Alliance
Details of the allianceSubscription for a third-party allotment (first stage: making REMED JAPAN an equity-method affiliate), Management Structure, Right to acquire additional shares (second stage: making REMED JAPAN a consolidated subsidiary), Use of funds, Exclusive distribution agreement and future developments
Number of shares acquired156,154 shares (35.0% voting rights ownership)
Acquisition price¥78,077,000
Shareholding ratio0.0% → 35.0%(Not disclosed)
Dispatch of directors and officersThe Company and REMED JAPAN are each expected to nominate 2 directors, and the Company is expected to appoint an audit & supervisory board member. One director from each company is expected to be appointed as representative director.
Numerical targets under the allianceThe Company will acquire 35% of REMED JAPAN’s voting rights and, in the second stage, is expected to exercise a call option during a specified period after finalization of the results for the fiscal year ending December 2028, increasing its voting interest to 51%.
Shareholding PolicyWhile the Company holds shares in REMED JAPAN, the exclusive distribution agreement may not be terminated, nor may prices be changed, without the Company’s consent. No additional acquisition exceeding 51% is currently planned.
Date of board resolution17 November 2026
Contract DateEarly December 2026 (予定)
Share Acquisition Date and Payment DateEarly December 2026 (予定)
Impact on Business PerformanceREMED JAPAN is expected to become an equity-method affiliate. The impact on the Company’s consolidated results has not been determined at this time, but is expected to be immaterial.
Items this document does not state (5)
Overview of the joint ventureOwnership ratioContract PeriodAlliance start dateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand product sales in Japan by linking REMED’s medical devices with the Company’s A-COMS customer network. In addition to operational cooperation between the two companies, the Company will strengthen the relationship and accelerate sales expansion through its capital participation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.